Literature DB >> 1614517

Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells.

M S Malnati1, M Marti, T LaVaute, D Jaraquemada, W Biddison, R DeMars, E O Long.   

Abstract

Antigens presented to CD4+ T cells derive primarily from exogenous proteins that are processed into peptides capable of binding to class II major histocompatibility complex (MHC) molecules in an endocytic compartment. In contrast, antigens presented to CD8+ T cells derive mostly from proteins processed in the cytosol, and peptide loading onto class I MHC molecules in an early exocytic compartment is dependent on a transporter for antigen presentation encoded in the class II MHC region. Endogenous cytosolic antigen can also be presented by class II molecules. Here we show that, unlike class I-restricted recognition of antigen, HLA-DR1-restricted recognition of cytosolic antigen occurs in mutant cells without a transporter for antigen presentation. In contrast, DR1-restricted recognition of a short cytosolic peptide is dependent on such a transporter. Thus helper T-cell epitopes can be generated from cytosolic antigens by several mechanisms, one of which is distinct from the classical class I pathway.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1614517     DOI: 10.1038/357702a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  59 in total

Review 1.  Rous-Whipple Award Lecture. Chemical features of peptide selection by the class II histocompatibility molecules.

Authors:  E R Unanue
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

Review 2.  Diversity in MHC class II antigen presentation.

Authors:  John H Robinson; Alexei A Delvig
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

Review 3.  Beyond the classical: influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways.

Authors:  Laurence C Eisenlohr; Nancy Luckashenak; Sebastien Apcher; Michael A Miller; Gomathinayagam Sinnathamby
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

Review 4.  Crohn disease: a current perspective on genetics, autophagy and immunity.

Authors:  Thaddeus S Stappenbeck; John D Rioux; Atsushi Mizoguchi; Tatsuya Saitoh; Alan Huett; Arlette Darfeuille-Michaud; Tom Wileman; Noboru Mizushima; Simon Carding; Shizuo Akira; Miles Parkes; Ramnik J Xavier
Journal:  Autophagy       Date:  2011-04-01       Impact factor: 16.016

Review 5.  The elucidation of non-classical MHC class II antigen processing through the study of viral antigens.

Authors:  Asha Purnima Veerappan Ganesan; Laurence C Eisenlohr
Journal:  Curr Opin Virol       Date:  2017-01-12       Impact factor: 7.090

Review 6.  Presentation of cytosolic antigens via MHC class II molecules.

Authors:  Delu Zhou; Janice S Blum
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

7.  Association between the TAP1 gene codon 637 polymorphism and Graves' disease.

Authors:  Rong-Hsing Chen; Wen-Chi Chen; Ching-Chu Chen; Chang-Hai Tsai; Fuu-Jen Tsai
Journal:  Endocrine       Date:  2004-11       Impact factor: 3.633

8.  Sculpting MHC class II-restricted self and non-self peptidome by the class I Ag-processing machinery and its impact on Th-cell responses.

Authors:  Charles T Spencer; Srdjan M Dragovic; Stephanie B Conant; Jennifer J Gray; Mu Zheng; Parimal Samir; Xinnan Niu; Magdalini Moutaftsi; Luc Van Kaer; Alessandro Sette; Andrew J Link; Sebastian Joyce
Journal:  Eur J Immunol       Date:  2013-03-05       Impact factor: 5.532

9.  TAP1 gene AccI polymorphism is associated with atopic bronchial asthma.

Authors:  Liang-Wen Hang; Te-Chun Hsia; Wen-Chi Chen; Huey-Yi Chen; Fuu-Jen Tsai
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

10.  Processing of the DRB1*1103-restricted measles virus nucleoprotein determinant 185-199 in the endosomal compartment.

Authors:  S Demotz; W Ammerlaan; P Fournier; C P Muller; C Barbey
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.